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AbstrACt
Introduction Although cardiologists were ‘late-comers’ 
to the multidisciplinary team—contributing to the 
complex care of patients with Duchenne muscular 
dystrophy (DMD), they now recognise the importance 
of systematic cardiac surveillance and timely therapy 
to prolonged survival in patients with DMD. Empirical 
deployment of cardioactive medications has already 
improved outcomes, but the evidence base for clinical 
decision making is weak. Fundamental questions 
remain as to whether prophylactic therapy is justified 
and convincingly superior to prompt deployment of the 
same therapies once left ventricular (LV) dysfunction is 
detected. Even if it were, at what age should therapy be 
introduced and with what specific drugs?
Methods and analysis We are conducting a multicentre, 
parallel group, randomised, placebo-controlled study of 
combination therapy with an ACE inhibitor (perindopril) 
and a beta-blocker (bisoprolol) in boys with DMD aged 
5–13 years, with normal LV function by echocardiographic 
criteria at the time of recruitment. Boys are being 
followed-up for a minimum of 3 years and a maximum of 
5 years and undergo repeat assessments of LV function, 
heart rate and ECG, forced expiratory volume in the 1 s 
and forced vital capacity, adverse event reporting and 
quality of life at 6 monthly intervals. The primary outcome 
is change in LV function between active and placebo-
treated participants over the course of the study.
Ethics and dissemination The study was approved by 
‘NRES Committee East Midlands – Derby’. The results 
will be disseminated through manuscript publications, 
an international workshop and presentations to scientific 
meetings and parent forums.
translational aspects The study seeks to establish the 
evidence for prophylactic heart therapies for children with 
DMD, define the optimum age for their introduction and 
identify any safety concerns.
Article summary The protocol describes the design of an 
ongoing multicentre, double-blind, randomised placebo-
controlled study to establish the evidence for the use of 
prophylactic heart therapies in children with DMD, define 
the optimum age for their introduction and identify any 
safety concerns.
trial registration numbers EudraCT2007-005932-10 
and ISRCTN50395346; Pre-results.
IntroduCtIon 
Duchenne muscular dystrophy (DMD) is an 
X-linked recessively inherited neuromuscular 
disorder caused by a deficiency in the expres-
sion of the protein dystrophin on the inner 
aspect of muscle cell sarcolemma.1 Its clinical 
course has traditionally been characterised 
by weakness of proximal limb muscles and 
calf muscle hypertrophy and progresses to 
involve all body muscles.2 Affected individuals 
strengths and limitations of this study
 ► Double-blind, multicentre, randomised, place-
bo-controlled study design.
 ► Participants studied 6 monthly for a minimum of 3 
years.
 ► Largest study to date of prophylactic therapy for car-
diac dystrophinopathy.
 ► Use of echocardiographic assessments for primary 
endpoint measures.
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typically lose ambulation and become wheelchair-depen-
dent before the age of 13 years and die from cardiore-
spiratory failure in their third to fourth decade of age.3 4 
From the cardiology perspective, some 90% of men with 
DMD develop a severe, progressive form of cardiomy-
opathy. Twenty per cent to 30% have evidence of left 
ventricular (LV) impairment on echocardiography by 
age 10 years.5–8 Subtler abnormalities in LV function are 
evident in an even larger proportion of patients at all ages 
when more sensitive imaging techniques, such as tissue 
Doppler, magnetic resonance or metabolic imaging, are 
deployed.9 10 Despite the prevalence of cardiac involve-
ment, until recently cardiologists were not included in 
the multidisciplinary team managing patients with DMD. 
Historically, this was because survival in DMD was deter-
mined predominantly by respiratory muscle weakness 
and consequent respiratory failure. Despite the severity of 
underlying cardiomyopathy, patients with DMD remain 
asymptomatic because their limited physical activity, due 
to generalised muscle weakness, means that cardiac symp-
toms only emerge with the onset of heart failure. Even 
then, when cardiac medications were introduced, they 
were usually deployed tentatively and without any expec-
tation that they would improve survival.
However, life expectancy in DMD has improved over 
recent decades, primarily as a result of three changes: 
routine use of corticosteroid therapy for muscle strength-
ening, non-invasive ventilation for respiratory muscle 
weakness and wider multidisciplinary care arrange-
ments.11–13 This has meant that patients with DMD are 
now surviving routinely to an age when cardiac involve-
ment is more advanced and the heart more often contrib-
utes directly to death.6 12 13
The results of large randomised controlled trials in 
patients with idiopathic forms of dilated cardiomyop-
athy have established that cardioactive medications can 
reverse or change the trajectory of decline in LV dysfunc-
tion and so improve prognosis.14–16 Combination therapy 
with an ACE inhibitor (ACEi),17 18 beta-blocker19–21 and 
an aldosterone antagonist22 23 are now deployed routinely 
and well tolerated in adults. More recently, the findings 
from cohort series of patients with established cardiac 
dystrophinopathy have shown that the rate of decline in 
LV function can be slowed also by the same drug combi-
nations.24–27 However, when introduced after the detec-
tion of early, asymptomatic, LV systolic dysfunction, these 
therapies do not seem to be able to prevent a slower rate 
of decline over a longer period of time.25
objECtIvEs And hypothEsEs
The aim of this randomised, multicentre, placebo-con-
trolled trial is to determine whether the introduction of 
ACEi (perindopril) combined with beta-blocker (bisop-
rolol) therapy, before the onset of echo-detectable 
LV systolic dysfunction, can delay the age of onset and/or 
slow the rate of progression of cardiomyopathy compared 
with placebo in men aged 5–13 years with DMD. The 
study is being conducted at four National Health Service 
(NHS) specialist hospital sites. LV function will be assessed 
serially over a minimum of 3 years and a maximum of 
5 years. The study was designed on the assumption that 
only one high-quality placebo-controlled trial of prophy-
lactic cardioactive therapy is ever likely to be funded and 
brought to completion. Patient recruitment began in 
mid-2011 and the last participant was recruited in January 
2015. Patient follow-up is ongoing.
Primary hypothesis: starting the combination of perin-
dopril and bisoprolol before there is any evidence of 
LV systolic dysfunction, detectable by echocardiography, 
in children with DMD will delay the onset and/or slow 
the rate of progression of cardiac dystrophinopathy 
compared with placebo.
MEthods And AnAlysIs
patient and public involvement
The study was designed against the background of uncer-
tainties recognised both by clinicians and patient support 
groups about the value of prophylactic, cardio-specific 
medications for children with DMD and the optimum age 
to start therapy. This issue was a common theme raised 
by parents of boys attending cardiac surveillance clinics. 
This prompted the development of this clinical trial and 
the aims, study duration and the therapies to be tested 
evolved in discussion with patients/patient groups (eg, 
Action Duchenne, UK; an ENMC workshop with patient 
representatives; and so on) and clinician experts over 
several years. The burden of testing for the study was 
not specifically assessed with patients/patient but was 
designed to be intentionally low.
Eligibility criteria
At each of the four participating UK hospitals, boys 
with DMD attend neuromuscular clinics at least annu-
ally for supervision of musculoskeletal and respiratory 
function. Each hospital also has a regular schedule for 
cardiac surveillance, by which patients have LV function 
assessed every 2 years before the age of 10 years and annu-
ally thereafter in accordance with published DMD care 
recommendations.28 Males, aged 5 years to less than their 
13th birthday, with proximal muscle weakness and genet-
ically confirmed DMD (ie, an out-of-frame deletion or 
frameshifting point mutation in the dystrophin gene or 
less than 3% dystrophin expression on muscle biopsy by 
immunohistochemistry or western blot) were identified 
from their clinical records ahead of a scheduled neuro-
muscular or cardiology clinic attendance. The parent(s)/
legal guardian(s) of those not already receiving cardiac 
medications were contacted initially by letter, informed 
of the nature and purpose of the trial and invited to have 
their child participate. Parents and children received 
age-appropriate information documents about the study 
prior to attending a dedicated study screening clinic. 
Parents provided written consent, and as far as possible, 
the assent of children was also obtained prior to study 
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entry as required by local regulations. A screening log was 
kept by each site of those approached but not recruited 
to the study. Permission to use their child’s NHS number 
for tracing in the case of loss to follow-up and for assess-
ment of long-term survival status was also obtained from 
the parent(s)/legal guardian(s).
Boys then underwent baseline testing. This comprised 
an echocardiogram with tissue Doppler imaging, 12-lead 
ECG, vitalograph for forced vital capacity (FVC) and 
forced expiratory volume in the 1 s (FEV1) and peak flow 
measurements as well as blood sampling for haematology 
and biochemistry parameters. A parent and the boy also 
completed core and Neuromuscular disease specific 
module (NMD) module PedsQual quality of life ques-
tionnaires.29 30 To be eligible for randomisation and study 
enrolment, LV ejection fraction (LVEF), calculated by the 
16-segment wall motion score method, had to be ≥55%, 
fractional shortening (FS) ≥28% and there could not be 
any LV segmental hypokinesis on baseline echo imaging.
Additional inclusion/exclusion considerations
Current or recent inclusion in a separate natural history 
trial did not preclude participation in the DMD Heart 
Protection study. Patients with contraindications to either 
ACEi or beta-blocker medications were not recruited. 
Renal function was measured by plasma urea, creatinine 
and potassium prior to study entry. Patients with abnormal 
renal function (ie, creatinine>upper limit of local labora-
tory range; typically >60 mmol/L) or consistently abnor-
mally high serum potassium level (K>upper limit of local 
laboratory range; typically 5 mmol/L) were also excluded. 
To achieve blinding throughout the study, participants 
had to be able to swallow an empty capsule identical in 
size, colour and shape to that to be used throughout the 
study at the screening visit to be enrolled in the trial.
Randomisation, blinding and enrolment
Randomisation and dosing
To ensure concealment of allocation, randomisation was 
performed using the web-based Newcastle Clinical Trials 
Unit’s Randomisation Service in variable blocks, blocked 
and stratified by centre. Boys fulfilling study entry criteria 
were randomised to receive capsules containing both 
active medications (ie, perindopril 2 mg and bisoprolol 
1.25 mg) or an identical placebo capsule (ie, containing 
an inert filler). All participants took one capsule at 
bedtime for the first month and those weighing more 
than 30 kg then increased to two capsules at bedtime 
thereafter. If a participant’s weight increases to more than 
30 kg at any scheduled review, study medication increases 
to two capsules per day for the remainder of the study.
Blinding
Randomisation to active or placebo combined capsule 
(1:1 ratio) is double blinded from the point of manufac-
ture and identifiable only by a master code held at the 
Newcastle Clinical Trials Unit (NCTU). Participants, 
clinicians, pharmacy and other trial staff are also blinded 
to treatment allocation. Study drug and placebo capsules 
are identical in appearance and packaging, identifiable 
only through the study code numbers on the medica-
tion bottles. Following entry of a participant into the 
study, bottle numbers assigned to him are recorded on 
the prescription, and a list of bottles received by partici-
pants is maintained by the NCTU. Emergency code-break 
envelopes, one per participant, are stored in the trial 
pharmacy at sites to allow unblinding in the event of an 
emergency. Any unblinding is notified to the trial coor-
dinating team and a record will be maintained in both 
the Trial Master File and the Investigator Site File. Code 
breaks will not be performed routinely for participants on 
study completion.
Evaluation and follow-up 
All participants are being followed-up 6 monthly for a 
minimum of 3 years and a maximum of 5 years. At each 
attendance, participants have height and/or arm span, 
weight, blood pressure and heart rate measured, and the 
family is questioned about any adverse events, intercur-
rent illnesses and need for urgent or elective hospital 
admissions since last assessed. A list of all concomitant 
medications and any changes in doses are recorded. Boys 
have a repeat echocardiogram, 12-lead ECG, peak flow, 
FEV1 and FVC measurements and both the boy and a 
parent complete age-appropriate PedsQL, quality of life 
questionnaires. Families are instructed to bring all used 
and unused containers of trial medications back with 
them at each assessment as a way of assessing compliance 
with their allocated treatment (Table 1).
To increase the sensitivity of testing, cardiac MRI (cMRI) 
will be offered once to each participant as they exit the 
trial. This will allow supplementary measures of LVEF%, 
wall thicknesses, chamber dimensions and volume for 
comparisons between active and placebo cohorts in those 
who consent to this additional test.
Primary outcome variable
The primary outcome variable is change in LVEF%, 
derived from the 16-segment regional wall motion 
scoring system, compared with baseline between those 
receiving combination therapy or placebo over the 
duration of study participation. To assess the robustness 
of the echo-derived EF% result, similar comparisons 
will be made for other parameters of LV size and func-
tion, end-systolic and end-diastolic dimensions, LV wall 
motion index and LV-FS%. Prevalence of segmental, as 
opposed to global, cardiomyopathy will be compared 
by tissue Doppler imaging. LV diastolic function will be 
assessed using mitral-flow-to-left-ventricular-tissue-Dop-
pler ratios (E/E′ ratios).
Secondary outcome variables
cMRI measures of LV size and function as well as the pres-
ence, extent and distribution of intramyocardial fibrosis 
will be compared between active and placebo treated 
patients.
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Changes in quality of life measures over the duration of 
study participation will be compared between active and 
placebo treated participants using generic and muscle-spe-
cific PedsQL questionnaires.29 30 The cause of any deaths 
will be recorded and compared between groups as will 
the development of symptoms and/or signs of conges-
tive cardiac failure (CCF). For the purpose of this study, 
heart failure will be diagnosed by the onset of symptoms 
of orthopnoea with or without peripheral oedema and 
objective signs of heart failure—raised jugular venous 
pressure, third heart sound or gallop rhythm, pulmonary 
plethora on chest X-ray or similar—all in the context of 
known advanced LV dysfunction (ie, echocardiogram 
LVEF <25%). Patients who develop CCF will be withdrawn 
from intervention but invited to continue follow-up (as 
per protocol) and treated thereafter at the discretion of 
clinician managing the patient. However, given the age, 
study duration and requirement to have normal LV func-
tion by all criteria at study entry, it is not anticipated that 
any participant will meet this heart failure endpoint.
Participants who show a progressive reduction in 
LVEF% on at least two assessments at least 3 months 
apart, culminating in LVEF ≤35%, will be deemed to have 
reached a predefined study endpoint, mandating the 
introduction of active therapy. They will cease trial medi-
cations without being unblinded and convert to open-la-
belled ACEi and beta-blocker therapy. They will be asked 
to continue under study follow-up. This stipulation is to 
avoid participants being withdrawn on the basis of subtle 
changes in heart measures of dubious clinical significance 
that could subvert the aim of the study.
Definition of end of study
The end of study will be the last patient’s last visit, as 
agreed with the study sponsor.
Sample size calculation
The sample size was based on a composition of change in 
LVEF% over the 5-year term of the trial. A difference of 
5% between active and placebo-treated groups was consid-
ered to be the smallest that would represent a clinically 
useful gain. The SD of LVEF% has been taken to be 10%, 
and this gives two groups of 64 subjects to yield a power 
of 80% at the 5% significance level.31 By recruiting 140 
patients, allowance was made for an approximate 10% 
participant dropout rate from ‘ACE-inhibitor cough’. 
Since the age of onset of earliest detectable cardiomy-
opathy is variable, depending on age at recruitment, 
duration of follow-up, steroid use as well as any impact 
of specific DMD-mutations, it was not possible to factor 
these meaningfully into a power calculation.
Statistical analyses
Primary endpoints
All primary analyses will be by intention to treat, incor-
porating all randomised participants. Safety endpoints 
will be presented by groups as treated. Change in LVEF% 
from enrolment to end of trial will be assessed for each 
participant. Differences between treatment groups will 
be estimated using analysis of covariance (ANCOVA), 
with age, body surface area (using the Haycock formula), 
baseline LVEF%, steroid use and enrolling centre as 
covariates.
Secondary endpoints
ANCOVA will be used to examine differences between 
treatment groups in terms of LV-FS%, end-diastolic 
dimension and wall motion scores, adjusted for baseline 
value, age, body surface area, steroid use and centre.
To assess robustness of LVEF% result, similar compar-
isons will be made for parameters of echo and MR-im-
aged LV end-systolic and end-diastolic dimensions, wall 
thicknesses, wall motion index and LV-FS%. ANCOVA 
will also be used to examine differences in regional LV 
systolic function between treatment groups in terms of 
tissue–Doppler ratios.
From late-Gad-enhanced cMRI images at study exit, 
measures of LVEF%, wall thicknesses, chamber dimen-
sions and volume and presence/extent of LV myocardial 
fibrosis will be obtained and compared between active 
and placebo participants.
The age of onset of earliest definite, echo-detectable 
impairment of LV function (ie, wall motion abnormality 
in >2 contiguous LV segments, ejection fraction >2 SDs 
below mean for age) will be plotted for each group over 
the 5-year course of the trial and active-treated and place-
bo-treated groups will be compared using Kaplan-Meier 
plots.
Changes in quality of life measures (core, NMD-specific 
and parent proxy PedsQL modules) within participants 
over the course of the trial and between participants in 
active-treated and placebo-treated arms will be assessed 
and resulting scores compared.
Safety endpoints will be presented descriptively; no 
formal testing will be performed.
Full details of statistical analysis will be documented in 
a Statistical Analysis Plan that will be signed off prior to 
database lock. Subgroup analyses will be used to adjust 
comparisons for baseline variables (eg, age at recruit-
ment, duration of study participation and steroid use).
Ethics and dissemination
The results will be disseminated through various manu-
script publications focusing on different outputs from 
the study and presentations of results at local, national 
and international scientific meetings. Headline results 
will be fed back to participant families shortly after they 
become available by letter, which will also provide links 
to more detailed results (eg, study-related publications). 
Patient support group (eg, Action Duchenne, UK; Duchenne 
UK) have already offered to assist in publicising the 
results (eg, via their websites and patient-focused events). 
We also plan to convene an international workshop of 
experts, when all results are available, to discuss their 
implications and whether they should influence manage-
ment recommendations.
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Trial management and data monitoring and ethics committees
Trial steering committee
The Trial Steering Committee (TSC) is composed of an 
independent chair, independent statistician, the chief 
investigator/applicant and coapplicants, sponsor/funder 
representative and representatives of the clinical trials 
unit (statistician and trial manager). The TSC met twice 
in the first year and meets annually thereafter. Its role 
is to supervise the trial to ensure that it is conducted to 
high standards in accordance with the protocol, the prin-
ciples of good clinical practice (GCP) and with regard to 
participant safety. The TSC also considers safety issues for 
the trial and relevant information from other sources, 
ensuring at all times that ethical considerations are met 
when recommending the continuation of the trial.
Data monitoring committee
A committee of three, comprising two clinicians and one 
statistician, all independent of the trial, act as the Data 
Monitoring and Ethics Committee. They met once at the 
beginning of the study to agree monitoring procedures, 
again in year 2 and are planned to meet finally in year 
4. As well as overseeing safety aspects, its role includes 
arbitrating in the case of any disagreements between the 
Principle Investigators (PI) at site and the CI over serious 
adverse events.
Trial management group
A trial management group consisting of the chief investi-
gator, senior trial manager, trial manager, statistician and 
trial data manager meets quarterly to discuss operational 
aspects of the trial.
Internal and external inspection
All aspects of the study are also subject to internal over-
sight by trial management team, internal inspection 
by representatives of the study sponsor and indepen-
dent external inspection by regulatory authorities (eg, 
Medicines and Healthcare products Regulatory Agency 
(MHRA)) who dictate their own frequency and depth of 
audit and inspection throughout.
data handling
A secure system of electronic case report forms is being 
used for data collection, management and monitoring. 
Only authorised users with appropriate access permis-
sions are able to enter/view/edit data.
All echocardiograms undertaken at recruiting site are 
being stored locally, and the anonymised images can be 
made available, if required, to NCTU for later analysis 
and validation of locally reported results. The quality 
and retention of study data are the responsibility of 
NCTU. Data are being collected to standards required 
by the latest directive on GCP (2005/28/EC) and local 
policy and will adhere to the Data Protection Act 1998. 
All study data will be archived in line with sponsor policy 
(currently15 years).
All investigators and their participating institutions 
are required to permit site monitoring, audits, Research 
Ethics Committee (REC) and MHRA review and must 
provide direct access to source data and documents as 
required for these purposes.
potential weaknesses in study design
This protocol was conceived originally at a time when 
cardiac medications were not prescribed routinely even 
for patients with DMD before the onset of symptomatic 
heart failure in most hospitals. Although the results of 
a randomised, placebo-controlled trial of prophylactic 
perindopril in DMD were known, their clinical signifi-
cance was debated.52 On this basis, it was concluded that 
another placebo-controlled study was both necessary and 
ethically justifiable.
Ideally, the study would have had four arms (perindopril 
alone, bisoprolol alone, perindopril and bisoprolol and 
placebo alone). However, it rapidly became apparent that 
there were insufficient potential participants available 
to recruiting sites to allow that design. Furthermore, the 
anticipated cost over the study duration planned would 
have been prohibitive. It was decided, therefore, that this 
protocol should build on the finding of the earlier perin-
dopril study by recruiting a larger patient cohort and by 
testing combination (perindopril and bisoprolol) rather 
than single agent (perindopril) therapy.
The optimum age at which to start prophylactic heart 
therapy is unknown. By recruiting participants as young 
as 5 years of age, the study aimed to check for intoler-
ance which might outweigh cardiac benefits, particularly 
in the very young. However, recognising that the youngest 
recruits were less likely to develop echo-detectable cardiac 
dysfunction over even the maximum study follow-up of 
5 years, the protocol included a prespecified analysis of 
results by age.
The decision to use echo rather than MR assessments 
for the main outcome measures was discussed repeat-
edly at the planning stage. Ultimately, echo measures 
were adopted for the following reasons: (1) young chil-
dren might not tolerate the length and nature of cMRI 
without sedation or general anaesthesia. Both were 
considered unreasonable in a research study planned in 
2009; (2) towards the end of study participation, older 
subjects might not be able to fit comfortably into an MRI 
scanner due to steroid induced changes in body habitus, 
scoliosis or limb contractures; and (3) because of respi-
ratory muscle weakness, older patients with DMD do not 
tolerate lying supine for long without assisted ventilation. 
Inability to breath-hold adequately and/or patient move-
ment reduce the image quality of cardiac MR scans and 
so their sensitivity in detecting subtler abnormalities. 
Furthermore, although cMRI is now used more routinely 
for surveillance and is more sensitive in detecting cardiac 
abnormalities at earlier stages in DMD, it was not as widely 
available in many hospitals in 2009.
A further important consideration was that if the find-
ings were ultimately to change the conservative approach 
to heart management that prevailed when the study was 
first approved, they would need to be sufficiently robust 
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to convince non-specialists of the benefits of prophylactic 
therapy. Also, allowing for wide variations in age of onset 
of detectable cardiac changes in DMD, a study of longer 
duration using less sensitive heart measures was consid-
ered more likely to provide clinically relevant answers 
than one of shorter duration even using more sensitive 
assessments. With the increased use and availability of 
cMRI since the study was first conceived, participants are 
now being offered cMRI once as they complete follow-up. 
This will increase the study’s ability to detect subtler 
differences in cardiac function and in fibrosis between 
active and placebo arms.
Each of the decisions made in developing the final 
protocol involved compromises and several can legiti-
mately be criticised. However, it is probably only after 
results become available that it will become clearer 
whether the best trade-offs were made and whether the 
protocol should have been optimised differently.
dIsCussIon
It has been known for decades that a progressive form of 
cardiomyopathy affects almost all patients with DMD.2 32–38 
LV function deteriorates progressively without symptoms 
for most of its course but ultimately contributes to heart 
failure and premature death in these patients.38 39 Tradi-
tionally, cardiac-specific medications were not deployed, 
because it was assumed that they would be of little benefit 
except in alleviating heart failure symptoms.40 41 This 
was based on the knowledge that none of them could 
correct the underlying dystrophin deficiency, which 
results in progressive cardiac myocyte damage from 
cardiac contractions. However, various cohort series have 
established that glucocorticoid steroid therapy delays the 
onset of cardiac dystrophinopathy42–46 and that a range of 
cardiac-specific drugs can slow the rate of deterioration in 
ventricular function when introduced after cardiomyop-
athy is detected.26 47–50
Based on current understanding of the cause and 
course of cardiomyopathy, therapies are more likely to be 
effective if started before the process has led to functional 
abnormalities.13 Support for the prophylactic use of ACEi 
therapy (perindopril) comes from the results of the only 
randomised, placebo-controlled trial in children with 
DMD. This found that, although mean LVEF% did not 
differ between treated and placebo groups after either 
three or 5 years, LVEF% fell to less than 45% after 5 years 
in eight of those initially receiving placebo as compared 
with only one taking perindopril.51 Additionally, early 
perindopril seemed to be associated with improved 
survival after 10 years.52 The results are encouraging but 
the findings have been criticised for a number of short-
comings in study design and the small trial size was not 
powered to detect a mortality outcome.
Some clinicians found the results persuasive and began 
to deploy prophylactic ACEi therapy routinely. However, 
others found the available evidence insufficient to 
justify daily drug-therapy for an average of 5 years before 
asymptomatic LV dysfunction would usually be detect-
able. The effect is that although steroid therapy is now 
recommended routinely for children with DMD, prophy-
lactic ACEi therapy is not, primarily because of the lack 
of convincing evidence of benefit. Furthermore, even if 
the benefits of prophylactic ACEi therapy are accepted, 
available evidence does not define the optimum age for 
their introduction. Nor is it established whether therapy 
should be with ACEi alone, ACEi and beta-blocker, aldo-
sterone antagonist alone or a combination of ACEi, beta-
blocker and aldosterone antagonist.27 It is even debated 
whether prophylactic cardiac therapy is really superior 
to the prompt introduction of combination cardiac ther-
apies on detecting the earliest evidence of ventricular 
dysfunction.53
This randomised placebo-controlled study protocol 
was developed in recognition of these therapeutic uncer-
tainties and to improve the evidence base for clinical 
decision making about how best to protect the hearts of 
children with DMD using currently available medications. 
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